Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Name: Αlpha¹ Rigor Record — Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Item: Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Rating: 59
Author: Αlpha¹

Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 4 high issues for “Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingData & code availability not met−0.5★
ReportingBiological variables partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced4 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Biological variables underreported (sex, age, strain)Assessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong phase 3 RCT with a well-founded scientific premise, rigorous randomization and powering, complete ethics reporting, and sound statistical reporting; the verification components found no statistical inconsistencies, no retracted/non-existent references, and no dead links. The principal weaknesses are the complete absence of a data availability statement (a critical trial-reporting gap) and partial reporting of biological variables (weight, race/ethnicity) and of the drug manufacturer.

Synthesis of two independent reviewer runs that converged on seven of eight dimensions; the sole divergence was biological variables (warn vs pass), resolved to warn on the strength of the jointly confirmed absence of weight and race/ethnicity. Statistics verification recomputed 2/2 reported tests consistently, but coverage is limited to tests reported with a test statistic + df or an effect estimate + CI; threshold-only and resampling-based p-values were not machine-checked and should be treated as unverified rather than confirmed. No retracted or not-found references and no dead reproducibility links were identified.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Reporting

Eight Dimensions5 pass · 2 warn · 1 fail

The introduction cites prior evidence on dMMR colon cancer, resistance to fluoropyrimidines, and the success of immunotherapy in metastatic disease. It provides a clear rationale for testing atezolizumab in the adjuvant setting. The paper acknowledges limitations such as the study design predating the IDEA collaboration and the immaturity of overall survival data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific foundation by citing prior research, providing a logical rationale for the study, and addressing limitations of prior work.

Evidence

direct quote[Introduction, paragraph 2]

“Evidence indicates that 10-15% of localized colon cancers show deficient DNA mismatch repair (MMR) that results in microsatellite instability-high (MSI-H) characterized by hypermutation immune checkpoint up-regulation, and abundant predicted neoantigens.”